Coming out strong

A Chinese public investor base could unlock the value that New WuXi Life Science Ltd. was unable to obtain on Wall Street. On March 23, WuXi announced that its main operating unit, WuXi AppTec, intends to return to the public markets, this time through an IPO in China.

The WuXi parent company was traded on the New York Stock Exchange until December 2015, when an investor syndicate led by Ally Bridge Group and WuXi Chairman and CEO Ge Li took the company private in a $3.3 billion deal (see BioCentury, Aug. 15, 2016). ...